Drugs / UF-KURE19
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05400109 | Apr 2023 → Oct 2026 expected | non-Hodgkin lymphoma | David Wald | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07713459 | Aug 2026 → Aug 2029 expected | diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma | Kure Cells, INC | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UF-KURE19 | “This is a Phase II, single-arm, open-label, interventional study designed to evaluate the efficacy of UF-KURE19, an autologous CD19-directed chimeric antigen receptor (CAR)...” NCT07713459 ↗ |
| Modality | Cell therapy | “The specific type of cells that will be used is called UF-KURE19 chimeric antigen receptor T cells (CAR-T cells).” NCT05400109 ↗ |
| Route | Intravenous | “Participants will receive a single intravenous infusion of UF-KURE19” NCT07713459 ↗ |
| Target | CD19 | “CD19-directed” NCT07713459 ↗ |